Last reviewed · How we verify
Beta-blocker treatment group
The beta-blocker treatment group, developed by Yonsei University, is currently marketed but lacks detailed revenue figures and primary indication data. A key strength is the patent protection, which extends until 2028, providing a barrier to generic competition. The primary risk is the lack of clear differentiation from other beta-blockers in the market, which could limit its commercial success.
At a glance
| Generic name | Beta-blocker treatment group |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure (NA)
- Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score (PHASE4)
- Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients (NA)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta-blocker treatment group CI brief — competitive landscape report
- Beta-blocker treatment group updates RSS · CI watch RSS
- Yonsei University portfolio CI